

10. (Amended) Method of using at least one of the active peptides of Claim 1 and/or at least one of their mimotopes for manufacturing a composition for application in liver diseases.

11. (Amended) Method of using at least one DNA that codes for at least one of the active peptides of Claim 1 for manufacturing a composition for application in liver diseases that optionally includes at least one of the mimotopes of the said active peptides.

12. (Amended) Method of using at least one recombinant expression system that codes for at least one of the active peptides of Claim 1 for manufacturing a composition for application in liver diseases that optionally includes at least one of the mimotopes for the said active peptides.

15. (Amended) Method according to Claim 11 for application to hepatic fibrosis.

REMARKS

The above amendatory action is taken for the purpose to avoid claim fees that would otherwise accrue due to the presence of multiply dependent claims.

Respectfully submitted,

William R. Evans

WILLIAM R. EVANS
LADAS & PARRY
26 WEST 61ST STREET
NEW YORK, NEW YORK 10023
REG.NO. 25,858 (212) 68-1930

Rg No 30086

MARK-UP

9. (Amended) Mimotopes of any of the active peptides of claim [Claims] 1 [to 8] characterized in that they display an antagonistic effect similar to them, but a longer average life in the body than the latter.

10. (Amended) Method of using at least one of the active peptides of claim [Claims] 1 [to 8] and/or at least one of their mimotopes for manufacturing a composition for application in liver diseases.

11. (Amended) Method of using at least one DNA that codes for at least one of the active peptides of claim [Claims] 1 [to 8] for manufacturing a composition for application in liver diseases that optionally includes at least one of the mimotopes of the said active peptides.

12. (Amended) Method of using at least one recombinant expression system that codes for at least one of the active peptides of claim [Claims] 1 [to 8] for manufacturing a composition for application in liver diseases that optionally includes at least one of the mimotopes of the said active peptides.

15. (Amended) Method according to claim [Claims] 11 [to 14] for application to hepatic fibrosis.